Optimizing glucocorticoid therapy in congenital adrenal hyperplasia and analog conditions: the intersection of dose reduction, patient care, and coverage in the US

BackgroundGlucocorticoid (GC) therapies treat many chronic conditions such as congenital adrenal hyperplasia (CAH), but long-term use carries risks of side effects (e.g., skeletal, cardiometabolic, mental health issues) that can negatively impact clinical and economic outcomes. Consequently, patient...

وصف كامل

التفاصيل البيبلوغرافية

الحاوية / القاعدة:	Frontiers in Endocrinology
المؤلفون الرئيسيون:	Ahmed Khattab, Hyunwoo Kim, Mary Mulrooney, Brian Leinwand, Nandini Hadker, Samantha Cicero, Henry Cheng
التنسيق:	مقال
اللغة:	الإنجليزية
منشور في:	Frontiers Media S.A. 2025-09-01
الموضوعات:	glucocorticoid-reducing therapies payer congenital adrenal hyperplasia survey corticosteroids glucocorticoid dose reduction
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fendo.2025.1603701/full